{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:25:33Z","timestamp":1789233933164,"version":"build-2803163510"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Chronic graft-vs-host disease (GVHD) limits the long-term benefit of haploidentical hematopoietic stem cell transplant (HSCT). This clinical trial evaluated repeated infusions of umbilical cord mesenchymal stem cells (MSCs) during the early stage (45 days and 100 days) after haplo-HSCT to prevent chronic GVHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether repeated infusions of MSCs during the early stage after haplo-HSCT decreases the incidence of severe chronic GVHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This open-label, multicenter, parallel randomized clinical trial was conducted from April 2016 to January 2022. Eligibility criteria included a diagnosis of acute leukemia and having a haploidentical, suitable related donor for HSCT. The median (range) follow-up time was 39.0 (1.5-67.0) months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>The enrolled patients with a haploidentical relative for HSCT received the modified busulfan\/cyclophosphamide + antithymocyte globulin modified regimen and standard GVHD prophylaxis. Patients were randomly chosen to receive MSCs (the MSC group) (1\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> cells\/kg, every 2 weeks, starting from 45 days after transplant, 4 times total) or regular prophylaxis (control group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome and Measure<\/jats:title><jats:p>The cumulative incidence of severe chronic GVHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 158 patients, 58 (36.7%) were female individuals; the median (range) age for the MSC and control groups was 28 (18-60) years and 28 (18-56) years, respectively. A total of 158 patients were screened, and 148 patients were randomly assigned to the MSC group (n\u2009=\u200974) or control group (n\u2009=\u200974) 1 day before MSCs infusion. The estimated 2-year cumulative incidence of severe chronic GVHD was 5.4% (95% CI, 1.8%-14.0%) in the MSC group and 17.4% (95% CI, 10.1%-28.5%) in the control group (hazard ratio [HR], 0.29; 95% CI, 0.10-0.88; <jats:italic>P<\/jats:italic>\u2009=\u2009.03). There was no difference between the MSC and control groups in the cumulative incidence of leukemia relapse (HR, 1.17; 95% CI, 0.55-2.47; <jats:italic>P<\/jats:italic>\u2009=\u2009.68). The cumulative incidence of stage II to IV acute GVHD in the MSC group was significantly lower than that in the control group (HR, 0.25; 95% CI, 0.09-0.67; <jats:italic>P<\/jats:italic>\u2009=\u2009.01). The MSC group had better GVHD-free and relapse-free survival rates than the control group (HR, 0.62; 95% CI, 0.39-0.98; <jats:italic>P<\/jats:italic>\u2009=\u2009.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The results of this randomized clinical trial show that early repeated infusions of MSCs decreased the incidence and severity of chronic GVHD, and the incidence and severity of acute GVHD manifested as a better GVHD-free and relapse-free survival rate for patients after haplo-HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>Chinese Clinical Trial Registry: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\/showproj.html?proj=13052\">ChiCTR-IIR-16007806<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.5757","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T16:32:33Z","timestamp":1703781153000},"page":"220","source":"Crossref","is-referenced-by-count":61,"title":["Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant"],"prefix":"10.1001","volume":"10","author":[{"given":"Ruihao","family":"Huang","sequence":"first","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanbin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, 920th Hospital of Joint Logistics Support Force, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hematology, the General Hospital of Western Theater Command, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Third Xiangya Hospital of Central South University, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, College of Military Preventive Medicine, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, College of Military Preventive Medicine, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyan","family":"Kong","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang F.","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"},{"name":"Jinfeng Laboratory, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"coi230077r1","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.bbmt.2020.01.022","article-title":"Systematic review of patient-reported outcome measures in graft-versus-host disease.","volume":"26","author":"Kilgour","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"coi230077r2","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"coi230077r3","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41423-021-00640-9","article-title":"Which is better, HLA-matched sibling or haploidentical transplantation?","volume":"18","author":"Zheng","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"coi230077r4","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","article-title":"Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.","volume":"18","author":"Guo","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"coi230077r5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41409-018-0239-9","article-title":"Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis.","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"coi230077r6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1182\/bloodadvances.2017006429","article-title":"The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis.","volume":"1","author":"Lorentino","year":"2017","journal-title":"Blood Adv"},{"issue":"22","key":"coi230077r7","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1182\/bloodadvances.2021005286","article-title":"Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival.","volume":"5","author":"Pidala","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"coi230077r8","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41409-020-0910-9","article-title":"Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile.","volume":"55","author":"van der Wagen","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"coi230077r9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.transproceed.2019.01.023","article-title":"Mesenchymal stem cells as a salvage treatment for severe refractory graft-vs-host disease in children after bone marrow transplantation.","volume":"51","author":"Krasowska-Kwiecien","year":"2019","journal-title":"Transplant Proc"},{"issue":"24","key":"coi230077r10","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","article-title":"Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord\u2013derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation.","volume":"34","author":"Gao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi230077r11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2307\/2531910","article-title":"Sample sizes based on the log-rank statistic in complex clinical trials.","volume":"44","author":"Lakatos","year":"1988","journal-title":"Biometrics"},{"issue":"1","key":"coi230077r12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.","volume":"55","author":"Styczynski","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"coi230077r13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/scd.2009.29.issue-4","article-title":"Karnofsky performance status scale.","volume":"29","author":"Friendlander","year":"2009","journal-title":"Spec Care Dentist"},{"issue":"1","key":"coi230077r14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"coi230077r15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8","key":"coi230077r16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"3","key":"coi230077r17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 Diagnosis and Staging Working Group report.","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"446","key":"coi230077r18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"20","key":"coi230077r19","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"coi230077r20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"6","key":"coi230077r21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/03007995.2018.1551193","article-title":"Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.","volume":"35","author":"Yu","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"coi230077r22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41409-022-01688-5","article-title":"Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients.","volume":"57","author":"Ding","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"coi230077r23","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/s41375-020-0733-0","article-title":"ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.","volume":"34","author":"Roy","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"coi230077r24","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.bbmt.2018.07.016","article-title":"Unexpected high incidence of human herpesvirus\u20136 encephalitis after naive T cell\u2013depleted graft of haploidentical stem cell transplantation in pediatric patients.","volume":"24","author":"Sisinni","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2813231\/jamaoncology_huang_2023_oi_230077_1707941333.21681.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:01:59Z","timestamp":1708012919000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2813231"}},"subtitle":["An Open-Label Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.5757","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}